FDA
-
-
-
-
-
-
-
LivaNova (LIVN) Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression
-
-
-
-
-
-
-
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
-
-
-
-
-
-
-
LivaNova Reports Third-Quarter 2023 Results
-
-
-
-
-
-
-
LivaNova Launches SenTiva DUO
-
-
-
-
-
-
-
LivaNova Reports Third-Quarter 2022 Results
-
-
-
-
-
-
-
Helius Medical Technologies, Inc. Appoints Paul Buckman to its Board of Directors
-
-
-
-
-
-
-
LivaNova Achieves Clinical Milestone in Heart Failure Program
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

